Hospenthal Duane R, Crouch Helen K, English Judith F, Leach Fluryanne, Pool Jane, Conger Nicholas G, Whitman Timothy J, Wortmann Glenn W, Robertson Janelle L, Murray Clinton K
Infectious Disease Service, Brooke Army Medical Center, Fort Sam Houston, Texas 78234, USA.
J Trauma. 2011 Jul;71(1 Suppl):S52-7. doi: 10.1097/TA.0b013e31822118fb.
Multidrug-resistant organism (MDRO) infections, including those secondary to Acinetobacter (ACB) and extended spectrum β-lactamase (ESBL)-producing Enterobacteriaceae (Escherichia coli and Klebsiella species) have complicated the care of combat-injured personnel during Operations Iraqi Freedom and Enduring Freedom. Data suggest that the source of these bacterial infections includes nosocomial transmission in both deployed hospitals and receiving military medical centers (MEDCENs). Admission screening for MDRO colonization has been established to monitor this problem and effectiveness of responses to it.
Admission colonization screening of injured personnel began in 2003 at the three US-based MEDCENs receiving the majority of combat-injured personnel. This was extended to Landstuhl Regional Medical Center (LRMC; Germany) in 2005. Focused on ACB initially, screening was expanded to include all MDROs in 2009 with a standardized screening strategy at LRMC and US-based MEDCENs for patients evacuated from the combat zone.
Eighteen thousand five hundred sixty of 21,272 patients admitted to the 4 MEDCENs in calendar years 2005 to 2009 were screened for MDRO colonization. Average admission ACB colonization rates at the US-based MEDCENs declined during this 5-year period from 21% (2005) to 4% (2009); as did rates at LRMC (7-1%). In the first year of screening for all MDROs, 6% (171 of 2,989) of patients were found colonized at admission, only 29% (50) with ACB. Fifty-seven percent of patients (98) were colonized with ESBL-producing E. coli and 11% (18) with ESBL-producing Klebsiella species.
Although colonization with ACB declined during the past 5 years, there seems to be replacement of this pathogen with ESBL-producing Enterobacteriaceae.
耐多药微生物(MDRO)感染,包括继发于不动杆菌(ACB)和产超广谱β-内酰胺酶(ESBL)的肠杆菌科细菌(大肠杆菌和克雷伯菌属)感染,在伊拉克自由行动和持久自由行动期间给战斗伤员的护理带来了复杂性。数据表明,这些细菌感染的来源包括部署医院和接收军事医疗中心(MEDCENs)的医院内传播。已开展MDRO定植的入院筛查以监测这一问题及其应对措施的有效性。
2003年,在美国接收大部分战斗伤员的三家军事医疗中心开始对受伤人员进行入院定植筛查。2005年,这一筛查扩展到兰施图尔地区医疗中心(LRMC;德国)。最初重点是ACB,2009年筛查范围扩大到所有MDRO,在LRMC和美国的军事医疗中心对从战区后送的患者采用标准化筛查策略。
2005年至2009年期间,4家军事医疗中心收治的21272例患者中有18560例接受了MDRO定植筛查。在此期间美国军事医疗中心的平均入院ACB定植率从2005年时的21%降至2009年的4%;LRMC的定植率也从7%降至1%。在对所有MDRO进行筛查的第一年,6%(2989例中的171例)的患者在入院时被发现定植,其中只有29%(50例)为ACB。57%(98例)的患者定植有产ESBL的大肠杆菌,11%(18例)定植有产ESBL的克雷伯菌属。
尽管过去5年中ACB定植有所下降,但似乎产ESBL的肠杆菌科细菌正在取代这种病原体。